CSI for CIU (Chronic Idiopathic Urticaria): Uncovering a Path of Relief for Our Youngest Patients CME

Allen Kaplan, MD, and Michael S. Blaiss, MD Author Information and Disclosures

Release Date: March 31, 2008; Valid for credit through March 31, 2009

Credits Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians

This activity is a CME monograph based on a Dinner Symposium, "CSI for CIU (Chronic Idiopathic Urticaria): Uncovering a Path of Relief for Our Youngest Patients," presented at the 2007 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology, which took place February 23, 2007, in San Diego, California.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Synergy Medical Education.
Sanofi Aventis
Learning Objectives
Upon completion of this activity, participants should be able to:
  • Discuss the pathophysiology and prevalence of CIU in the pediatric population
  • Recognize the clinical effects and impact of untreated CIU on the pediatric patient
  • Discuss the benefit and risks of various rational diagnosis and treatment approaches for CIU in the pediatric population, particularly school-aged children.
Author Disclosures
Michael Blaiss, MD
Disclosure: Served as speaker for Merck, GSK, Genentech, Novartis, Aventis, Alcon, King, Teva, Inspire, and AstraZeneca. He has also provided research support for GSK.

Allen Kaplan, MD
Disclosure: Served as speaker for Aventis and provided research support for Nippon Zoki Pharmaceuticals Ltd.
 
American Academy of Allergy, Asthma and Immunology
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Allergy, Asthma & Immunology (AAAAI) designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.